PSEN2
Presenilin-2
As of the edition of 20 October 2026, PSEN2 (presenilin-2, UniProt P49810) has 5 drugs tested at it and 4 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P49810
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 2
- Disease areas
- Cancer; Nervous system; Mental health; Skin and connective tissue; Digestive system; Urinary and reproductive; Hormones; Pregnancy and women's health
- Registered trials of its drugs
- 55
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 3 |
| Stopped | 2 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| RG-4733 | Stopped | Phase 2 | none listed |
| Avagacestat | Stopped | Phase 2 | none listed |
| Tarenflurbil | Went quiet | Phase 3 | none listed |
| Begacestat | Went quiet | Phase 1 | none listed |
| Semagacestat | Went quiet | Phase 3 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Roche | Route A |
| Bristol Myers Squibb | Route A |
| Eli Lilly | Route A |
The other 1 company at PSEN2
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at PSEN2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.